Calistoga (Seattle, WA) a spinout of Icos, is developing compounds targeting p110 delta for cancer, inflammatory and autoimmune indications raised $21M in a series A round. The financing was led by Frazier Healthcare Ventures and Alta Partners and joined by Three Arch Partners and Amgen Ventures.

Omeros (Seattle, WA) a biopharmaceutical company focused on improving joint function following arthroscopic surgeries raised $63M in a Series E financing. Investors included Aravis Ventures, Arch Venture Partners, American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, and Trevi Health Ventures.

Blue Heron Biotechnology (Bothell, WA) a provider of gene synthesis services raised approximately $3.7M in Series D funding. Participants include Crabtree Ventures, Integra Ventures and Invitrogen.

EyeGate Pharma (Waltham, MA) a pharmaceutical company pioneering the use of iontophoresis technology to deliver therapeutics for ocular indications, announced that it has closed on a $2M extension of its Series B, bringing the total of the financing to $12M. This funding comes from the Nexus Group, the round was originally led by Innoven Partenaires [...]